Volume 22, Number 3—March 2016
Research
Encephalitis, Ontario, Canada, 2002–2013
Table 4
Variable* | No. (%) cases | Mean length of hospitalization, d (median) | Exponentiated β-coefficient (95% CI) | t | p value |
---|---|---|---|---|---|
Intercept |
8.9 (8.0–9.8) |
41.0 |
<0.0001 |
||
Encephalitis cause | |||||
Viral | 1,788 (27.7) | 27.36 (14) | |||
Bacterial | 152 (2.4) | 27.45 (19) | 1.2 (1.0–1.4) | 1.5 | 0.128 |
Amebic/parasitic/fungal | 92 (1.4) | 43.17 (18) | 1.3 (1.0–1.6) | 2.1 | 0.038 |
Immune mediated | 657 (10.2) | 26.37 (14) | 1.1 (1.0–1.2) | 1.8 | 0.0804 |
Other | 466 (7.2) | 24.33 (11) | 0.9 (0.8–1.0) | −1.7 | 0.0817 |
Unknown | 3,299 (51.0) | 19.79 (9) | 0.8 (0.7–0.8) | −7.8 | <0.0001 |
Unable to classify |
9 (0.1) |
38.78 (16) |
2.1 (1.0–4.1) |
2.0 |
0.0448 |
Sex | |||||
M | 3,417 (52.8) | 23.07 (11) | |||
F |
3,046 (47.1) |
23.82 (12) |
1.0 (1.0–1.1) |
0.9 |
0.3634 |
Age group, y | |||||
<1 | 173 (2.7) | 22.83 (16) | 1.0 (0.8–1.1) | −0.6 | 0.55 |
1–4 | 377 (5.8) | 12.28 (5) | 0.6 (0.5–0.7) | −8.6 | <0.0001 |
5–19 | 915 (14.2) | 14.54 (6) | 0.8 (0.8–0.9) | −8.4 | <0.0001 |
20–44 | 1,486 (23.0) | 23.27 (9) | 0.8 (0.8–0.9) | −3.6 | 0.0003 |
45–64 | 1,823 (28.2) | 25.02 (13) | |||
>65 |
1,689 (26.1) |
29.19 (17) |
1.1 (1.1–1.2) |
3.7 |
0.0003 |
Immune status | |||||
Immunocompetent | 5,525 (85.5) | 21.29 (10) | |||
Immunocompromised |
938 (14.5) |
35.99 (19) |
1.3 (1.2–1.4) |
5.6 |
<0.0001 |
Co-morbidity level† | |||||
None | 3718 (57.5) | 14.05 (8) | |||
Low | 564 (8.7) | 26.08 (14) | 1.7 (1.6–1.9) | 11.0 | <0.0001 |
Moderate | 911 (14.1) | 26.13 (15) | 1.8 (1.7–2.0) | 14.8 | <0.0001 |
High | 575 (8.9) | 39.00 (25) | 2.8 (2.6–3.1) | 21.2 | <0.0001 |
Very high | 520 (8.1) | 55.28 (36) | 4.0 (3.6–4.4) | 27.0 | <0.0001 |
Missing data | 175 (2.7) | 14.05 (41) | 4.4 (3.7–5.2) | 17.9 | <0.0001 |
*Season, year, and patient Local Health Integration Network were not found to cause a significant change (>20%) in the parameter estimates for the exposure variable (category of encephalitis cause) and were thus excluded from the mode.
†Case mix grouping plus comorbidity levels are based on cumulative cost impact of comorbidities on patient stay, where "none" represents no impact and "very high” represents the greatest impact.
1Current affiliation: Yale School of Public Health, New Haven, Connecticut, USA.
Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.